SEC Comment Letter for Zomedica Corp. (ZOM) (CIK 0001684144) (ZOMDF) — May 19, 2020
Zomedica Corp. (ZOM) (CIK 0001684144)
Date: May 19, 2020 · CIK: 0001684144 · Accession: 0000000000-20-004461
AI Filing Summary & Sentiment
File numbers found in text: 333-238322
Letter
United States securities and exchange commission logo May 19, 2020 Shameze Rampertab Interim Executive Officer and Chief Financial Officer Zomedica Pharmaceuticals Corp. 100 Phoenix Drive, Suite 180 Ann Arbor, Michigan 48108 Re:Zomedica Pharmaceuticals Corp. Registration Statement on Form S-1 Filed May 15, 2020 File No. 333-238322 Dear Mr. Rampertab: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at (202) 551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John D. Hogoboom
Show Raw Text
United States securities and exchange commission logo
May 19, 2020
Shameze Rampertab
Interim Executive Officer and Chief Financial Officer
Zomedica Pharmaceuticals Corp.
100 Phoenix Drive, Suite 180
Ann Arbor, Michigan 48108
Re:Zomedica Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed May 15, 2020
File No. 333-238322
Dear Mr. Rampertab:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason L. Drory at (202) 551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John D. Hogoboom